Clinical Trials Directory

Trials / Recruiting

RecruitingNCT00457847

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

Genetics of Primary Graft Dysfunction

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,150 (estimated)
Sponsor
University of Pennsylvania · Academic / Other
Sex
All
Age
15 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Primary graft dysfunction (PGD) is a severe lung injury that can occur in the days following lung transplant surgery. The purpose of this study is to identify genetic factors that may put someone at risk for developing PGD.

Detailed description

PGD is a severe complication that affects up to 25% of lung transplant patients following surgery. Pulmonary edema, which is an abnormal build-up of fluid in the lungs, and hypoxemia, which is low blood oxygen levels, are two common symptoms that individuals with PGD experience. Treatment for this condition is often expensive, and it is the leading cause of death following lung transplant. Many potential donors and recipients are considered unsuitable for lung transplant because of concern for the development of PGD. Therefore, the ability to accurately predict which individuals are at risk for developing PGD may allow more lung transplants to be performed. Specific characteristics in both lung donors and recipients may play an important role in determining the risk of PGD. For example, genetic variations in how the body deals with harmful chemicals called oxidants may be associated with the development of PGD. The purpose of this study is to identify the specific genetic biomarkers in donors and recipients that put individuals at risk for developing PGD following a lung transplant. This study will enroll individuals who are undergoing lung transplantation. Blood samples will be collected from lung donors and from participants prior to surgery, immediately following surgery, and 24 hours after surgery. Study researchers will monitor participants for 72 hours following surgery for symptoms of PGD. There will be no additional study visits.

Conditions

Timeline

Start date
2007-02-01
Primary completion
2026-06-01
Completion
2026-06-01
First posted
2007-04-09
Last updated
2025-07-16

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00457847. Inclusion in this directory is not an endorsement.